Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Clinical Study Evaluating the Efficacy and Safety of CM338 Injection in Subjects With Immunoglobulin A Nephropathy

NCT05775042 is registered in ClinicalTrials.gov with Keymed Biosciences Co.Ltd as lead sponsor.

NCT NCT05775042
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05775042 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Clinical Study Evaluating the Efficacy and Safety of CM338 Injection in Subjects With Immunoglobulin A Nephropathy
Lead sponsor
Keymed Biosciences Co.Ltd
Phase
Phase 2
Overall status
Recruiting
Start date
May 8, 2023
Completion date
June 30, 2027
Enrollment
70 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

iga nephropathy